Silence Therapeutics (SLN) Stock Forecast and Price Target (2026)

Last updated November 2026

Short answer

4 analysts covering Silence Therapeutics (SLN) carry an average price target of $19.75 as of November 2026, -0.3% against the $19.80 share price on November 16, 2026. The published targets run from $19.00 to $20.00, a spread of 5% of the average, so the disagreement is narrow. The rating split is 1 buy, 4 hold, 0 sell. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market. Walnut is not an investment adviser.

SLN analyst price targets

Price
$19.80
Average target
$19.75
Median target
$20.00
Implied vs price
-0.3%
Target range
$19.00 to $20.00
Analysts covering
4
Ratings
1 buy4 hold0 sell

SLN analyst data as of November 2026, sourced from Yahoo Finance and may be delayed. The price is the last one Yahoo Finance reported on November 16, 2026.A price target is what an analyst published on a date, not a forecast Walnut endorses, and targets are typically set on a 12-month view. Verify current figures before deciding.

The average target of $19.75 sits roughly in line with the $19.80 price, -0.3%. The median is $20.00, and where the two differ the median is the steadier read, because one unusually high or low target cannot drag it.

What the SLN target range actually tells you

The published targets span $19.00 to $20.00. That gap is 5% of the average target, which counts as narrow disagreement. A spread that tight means the analysts broadly agree on the model, so the consensus is a reasonably stable read of a shared view.

The useful move is to read the high target as one bull scenario and the low target as one bear scenario, then ask which set of assumptions you find more plausible. Both cases are worked through on the SLN is it a buy page.

Recent analyst actions on SLN

FirmActionTargetPriorDate
HC Wainwright & Co.Lowered (Neutral)$20.00$75.00October 21, 2026
Morgan StanleyRaised (Overweight)$32.00$25.00August 11, 2026
Cantor FitzgeraldInitiated (Overweight)--June 24, 2026
HC Wainwright & Co.Maintained (Buy)$75.00$75.00June 17, 2026

The most recent published rating actions on SLN within the last six months, from Yahoo Finance. Each row is dated because a target only means something alongside the date it was set. Walnut is not an investment adviser and does not endorse any of these views.

In the last six months there has been 1 raise and 1 cut among these actions. The direction of revisions is often more telling than the level, because it shows which way informed opinion is moving.

How analysts rate SLN

Of the analysts with a published rating, 1 say buy, 4 say hold, and 0 say sell, so 20% carry a buy. That buy share has fallen over the last three months, so sentiment is drifting more negative.

The distribution says more than the label. Sell ratings are rare across the entire market for structural reasons, so a stock with no sell ratings is unremarkable, while even a handful of them is worth understanding.

Why a SLN price target is not a prediction

  • It is a 12-month model output. An analyst picks assumptions for revenue, margin, and a multiple, and the target falls out of the arithmetic. Change one assumption and the target moves a lot.
  • The distribution is skewed. Sell-side coverage carries far more buy ratings than sell ratings across the whole market, so the average is not a balanced vote.
  • Targets follow price as often as they lead it. Revisions frequently arrive after a move, not before, which is why a rising target is weak evidence on its own.
  • Nobody is scored on it. There is no cost to a target that never gets close, so treat accuracy as unverified unless you check the firm's record yourself.

SLN earnings and revenue forecast

For the fiscal year ending Dec 2026, the 7 analysts publishing estimates on SLN expect earnings of -$0.36 per share and revenue of 328.8 thousand GBP (-21%).

PeriodEPS estimateEPS growthRevenue estimateRevenue growth
Quarter ending Sep 2026
next quarter to report, 6 analysts
-$0.09n/a20.8 thousand GBP
0 thousand GBP to 125 thousand GBP
-83%
Quarter ending Dec 2026
the quarter after, 6 analysts
-$0.10n/a4.5 thousand GBP
0 thousand GBP to 27 thousand GBP
-82%
Fiscal year ending Dec 2026
fiscal year next to report, 7 analysts
-$0.36
-$0.37 to -$0.36
n/a328.8 thousand GBP
299 thousand GBP to 469 thousand GBP
-21%
Fiscal year ending Dec 2027
the fiscal year after, 7 analysts
-$0.38n/a760.5 thousand GBP
0 thousand GBP to 4.5 million GBP
+131%

Consensus estimates for SLN published by sell-side analysts, as of November 2026, from Yahoo Finance. Each figure is the average of the analysts counted, with the lowest and highest estimate beneath it; growth compares with the same period a year earlier and is left blank where either figure is a loss. Estimates change constantly. Walnut is not an investment adviser.

Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level. Silence Therapeutics next reports around November 12, 2026 (an estimated date), which is when these figures get tested against actual results.

Is there a 2030 forecast for SLN?

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering SLN do not put out a 2030 number. Anything presenting one is extrapolating a growth rate of its own, and a figure produced that way tells you about the assumption chosen, not about the company.

What can be said over a long horizon is what the current price already assumes about the business, which is a question the filings answer and a forecast cannot.

For a ten-year question, that frame is more useful. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Silence Therapeutics can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

What could move SLN from here

In short: the drivers cited most often are Divesiran after a positive SANRECO Phase 2, A partner for zerlasiran, A larger cash pile after the August raise. The risk cited most often against it is silence generates essentially no product revenue, so the equity is a claim on clinical outcomes and financing terms rather than on earnings.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the SLN is it a buy page.

Your questions about Silence Therapeutics

Ask Walnut's AI anything about SLN and see how it fits what you own.

FAQ

What is the price target for Silence Therapeutics (SLN)?

+

The average analyst price target for SLN is $19.75 as of November 2026, across 4 analysts. The average is -0.3% against the $19.80 share price on November 16, 2026, so the consensus sits roughly in line with where the stock trades. The median target, which is less distorted by one extreme view, is $20.00. Targets move constantly; verify the current figure before relying on it.

How high could SLN go?

+

The highest published target is $20.00, which is +1.0% against the $19.80 price. It is one analyst's most optimistic case, not a ceiling and not a forecast. The lowest is $19.00. The gap between them answers this question best: analysts who all follow Silence Therapeutics closely disagree by 5% of the average target, so treat any single number as one scenario.

How many analysts cover SLN?

+

4 analysts publish estimates on SLN as of November 2026. Of those with a published rating, 1 say buy, 4 hold, and 0 sell, so 20% carry a buy rating. More coverage usually means the consensus is better informed, though it also means the obvious points are already in the price.

Are analyst price targets for SLN accurate?

+

Treat them as informed opinion, not measurement. Two things matter here. Sell-side ratings skew positive across the market, and SLN is no exception at 20% buy ratings, so the distribution is not a balanced vote. And targets tend to follow the share price at least as often as they lead it, getting raised after a stock has already run. They are most useful as a read on what the informed consensus expects, and least useful as a prediction of where the price lands.

Has the SLN price target been raised or cut recently?

+

In the last six months there has been 1 raise and 1 cut among the published actions on SLN. The most recent was HC Wainwright & Co., which lowered its target to $20.00 from $75.00 on October 21, 2026. The direction of revisions often tells you more than the level, because it shows which way the informed view is moving.

Is analyst sentiment on SLN improving?

+

Over the last three months the share of analysts rating SLN a buy has been falling. The shift is in opinion, not in the business, and it often lags the news that caused it. It is best read alongside the target revisions.

What are analysts' earnings estimates for Silence Therapeutics (SLN)?

+

For the fiscal year ending Dec 2026, the 7 analysts publishing estimates on SLN expect earnings of -$0.36 per share and revenue of 328.8 thousand GBP (-21%). For the fiscal year ending Dec 2027, the consensus is -$0.38 per share. These are consensus estimates as of November 2026, the average of what the covering analysts publish, and they are revised constantly, especially around each earnings report. They describe expectations, not results.

When does SLN report earnings next?

+

Silence Therapeutics's next earnings report is expected around November 12, 2026, a date estimated from its reporting history that the company has not yet confirmed. The report is when the estimates on this page get tested against actual results, which is why targets and estimates tend to move most in the days after it.

What is the SLN stock price prediction for 2030?

+

There is no published one. Analyst targets run to about twelve months and no firm covering SLN publishes a 2030 figure, so any site showing one has extrapolated a growth rate of its own. The answerable version of the question is what the current price already assumes about Silence Therapeutics's earnings, which the forward multiple on this page sets out, and what would have to change for that to break.

Will SLN go up in 2026?

+

Nobody knows, including the analysts publishing targets. What the numbers on this page tell you is where informed opinion currently sits and how much it disagrees with itself, which is useful and different from a prediction. The risk most often cited against Silence Therapeutics: Silence generates essentially no product revenue, so the equity is a claim on clinical outcomes and financing terms rather than on earnings. Walnut is not an investment adviser.

Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a November 2026 data pull of published third-party research, are approximate, and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026, and every percentage against it on this page is measured from that price. Verify current figures with your broker before acting on them.

Forecasts for similar stocks